Thailand

On January 1, 2025, Thailand’s Revenue Department began enforcing the Emergency Decree on Top-up Tax B.E. 2567 (2024), marking a significant step for Thailand toward implementing the OECD’s Global Anti-Base Erosion Model Rules under Pillar Two. This issuance aims to reduce tax competitions among countries by ensuring that in-scope multinational enterprise (MNE) groups are subject to an effective tax rate (ETR) of at least 15%. Under this Emergency Decree, Thailand’s Revenue Department is authorized to collect Top-up Tax from MNEs operating in Thailand where the applicable ETR falls below the minimum threshold. This introduction may inevitably raise concerns among MNEs that have benefited under Thailand’s Board of Investment (BOI) as the BOI-granted tax incentives may trigger additional Top-up Tax liabilities. In response, on November 12, 2025, the BOI, in collaboration with the Ministry of Finance, announced that it is in the process of revising the National Competitiveness Enhancement for Targeted Industries Act B.E. 2560 (2017) by introducing a Qualified Refundable Tax Credit (QRTC), which is a mechanism recognized by the OECD. This new form of incentive reflects a policy response aimed at aligning Thailand’s investment promotion regime with the OECD’s global minimum tax framework. However, this incentive is intended to be offered as an alternative measure for MNEs affected by the Emergency Decree, not to replace the offering of incentives. This means that investors who are not subject to the Emergency Decree can continuously benefit from the BOI-granted incentives as in the past. Furthermore, on December 30, 2025, Thailand’s Cabinet approved four draft secondary legislations issued in pursuance to the Emergency Decree, which were developed in accordance with the OECD’s GloBE Model Rules and Commentaries, with the objectives of ensuring consistency with the international practices. The approved drafts address the detailed rules, including but not limited to the determination of in-scope MNEs and the approach for calculating Top-up Tax liabilities that such taxpayers are subject to under the Emergency Decree. The four draft laws are as follows: Royal Decree prescribing the criteria for determining whether multinational enterprise groups that have undergone organizational restructuring are subject to the Top-up Tax; Ministerial Regulation prescribing the criteria concerning entities that are not constituent entities; Ministerial Regulation prescribing the criteria for allocating Top-up Tax to Thailand under the Undertaxed Payments Rule (UTPR) mechanism in cases where no constituent enterprise group located in Thailand has GloBE income; and Ministerial Regulation prescribing the criteria for adjusting income, expenses, and covered taxes for the calculation of the Top-up Tax, including the criteria for calculating the Domestic Top-up Tax in Thailand. Overall, these developments signal Thailand’s progress toward implementing the global minimum tax framework. However, further updates on their key aspects will be provided once the detailed rules become available. Article by Senior Partner Sumet Mingmongkolmitr

The Department of Intellectual Property (DIP) of Thailand has announced the reclassification of certain goods under the 13th Edition of the Nice Classification, (NCL 13), which will take effect in 2026. This update aligns Thailand’s trademark classification system with the latest international standards and may affect both pending and future trademark applications.   Key changes include the transfer of several product groups to new classes, including: Eyewear and lenses: Eyeglasses, sunglasses, contact lenses, frames, and related accessories will be reclassified from Class 9 to Class 10. Safety and rescue equipment: Fire engines, fire boats, lifeboats, life rafts, and evacuation chairs will be reclassified from Class 9 to Class 12. Electrically heated clothing and accessories: Heated garments, heated socks, and electrically heated footmuffs will be reclassified from Class 11 to Class 25.   The DIP also announced reclassification for several individual goods, including: terpenes, which will move from Class 3 to Class 1; tongue scrapers, from Class 10 to Class 21; watering hose nozzles, from Class 21 to Class 17; surf skis, from Class 28 to Class 12; and buttercream (icing), from Class 29 to Class 30.   According to the DIP’s announcement, applicants who file the trademark application before 31 January 2026 may continue using the existing classification. However, once the marks are registered, the new class positions under NCL 13 will apply upon renewal. Trademark owners are therefore advised to review their current trademark portfolios and upcoming filings to ensure that goods are correctly classified under the revised system, so as to avoid procedural issues and ensure continuous protection.   For more information or inquiries regarding trademarks or intellectual property in Thailand, please contact our IP professionals at [email protected].   Reference: The reclassification of certain goods under the 13th Edition of the Nice Classification (NCL 13) can be retrieved at this link.   Author:   Dr. Pollawat Suppattarasaet, IP Partner; and Thamolwan Insawang, Associate.   They can be reach at [email protected]

Cannabis Legal History in Thailand Thailand has a long and complex relationship with cannabis. Historically, cannabis (ganja) was widely used for medical, culinary, and cultural purposes. For centuries, Thai traditional medicine employed cannabis extracts as remedies for pain relief, appetite stimulation, and treatment of various ailments. However, under the Narcotics Act B.E. 2522 (1979), cannabis was classified as a Category 5 narcotic, rendering its cultivation, possession, and use strictly illegal. Penalties for violations included imprisonment and heavy fines, and the substance became stigmatized as part of broader international anti-drug campaigns The turning point began in the late 2010s, when global shifts toward decriminalization and medical legalization influenced Thailand’s domestic policy. In 2018, Thailand became the first country in Southeast Asia to legalize cannabis for medical and research purposes (Narcotics Act (No. 7) B.E. 2562 (2019)), allowing the limited use of cannabis oil, extracts, and research-based cultivation. At that time, operators were required to work closely with public agencies, such as universities and government hospitals, to cultivate and extract cannabis. In June 2022, cannabis was officially decriminalized through its removal from the Narcotics List under the Ministerial Notification of the Ministry of Public Health (No. 8) B.E. 2565 (2022). This sparked a rapid proliferation of cannabis-related businesses, from dispensaries and cafes to wellness centers and agricultural ventures. Nevertheless, the swift liberalization also triggered regulatory uncertainty and social debates. The lack of comprehensive oversight, concerns about recreational misuse, and rising public health risks pushed policymakers to reintroduce tighter controls, culminating in the Cannabis and Hemp Control Act (Draft Bill, 2024–2025) and ministerial notifications that now aim to balance economic opportunity with public health and social order. New Approach of Legal Laws and Regulations in Thailand 2.1 Current Legal Framework Following decriminalization in June 2022, cannabis entered a “grey zone” of regulation. Businesses mushroomed quickly, taking advantage of unclear restrictions, especially regarding recreational use. However, by mid-2025, the Thai government introduced new legislation and ministerial regulations to formally control cannabis cultivation, distribution, marketing, and consumption. Key provisions include: Cultivation Standards: The Cultivation of cannabis and hemp requires compliance with Thai GACP (Good Agricultural and Collection Practices) standards, ensuring both quality and traceability of cannabis flowers. Licensing Requirements: Cultivation, import/export, sales, and processing of cannabis require specific licenses issued by the Food and Drug Administration (FDA) and relevant ministries under the Public Health Act B.E. 2535 (1992) and ministerial notifications. Medical-Only Orientation: Cannabis is recognized as a controlled plant for medical and health purposes. Recreational use remains outside the scope of the law and is implicitly prohibited. Doctor’s Prescription Requirement: Any sale of cannabis flowers intended for smoking or direct consumption must be tied to medical use and supported by a prescription from a licensed physician (Ministerial Notification on Controlled Cannabis Products B.E. 2566 (2023)). Any cannabis distillate, extract, or oil with THC exceeding 0.2% w/w is classified as a controlled substance under the Narcotics Act and may only be dispensed upon a doctor’s prescription. Extracts with THC not exceeding 0.2% w/w may be incorporated into cosmetics, herbal products, or food supplements, subject to FDA product registration, quality controls, and labeling requirements. Usage Restrictions: Smoking cannabis in public places remains subject to penalties under the Public Health Act for public nuisance. Marketing and advertising are prohibited from promoting recreational consumption or from targeting minors (Ministerial Regulation on Cannabis Advertising B.E. 2566 (2023)). Import & Export Controls: Cross-border trade in cannabis or hemp requires pre-approval from the Ministry of Public Health, in line with Thailand’s obligations under the Single Convention on Narcotic Drugs 1961 and domestic legislation. 2.2 Impact on Businesses These rules have reshaped the cannabis landscape. Dispensaries and recreational-style outlets face heightened scrutiny, while medical clinics, licensed manufacturing plants, pharmaceutical companies, and wellness enterprises benefit from clearer compliance pathways. Notably, businesses engaged in the sale of cannabis flowers or high-THC distillates (>0.2% THC w/w) must operate strictly as medical establishments and employing licensed doctors authorized to prescribe cannabis products. This effectively transforms retail-style models into clinically regulated practices, raising compliance and operational costs. Foreign investment in cannabis remains restricted under the Foreign Business Act B.E. 2542 (1999), which caps foreign ownership in the agricultural and service sectors unless exemptions are granted. While the Board of Investment (BOI) offers privileges for certain high-value industries, cannabis has not yet been included in BOI-promoted activities. In practice, without a permanent Cannabis Act, obtaining BOI promotion for cannabis businesses is unlikely. Additionally, intellectual property (IP) protections for cannabis strains, cultivation techniques, and extraction processes are increasingly important, as licensing agreements and IP filings help safeguard competitiveness in a regulated market. The Future of Cannabis Business in Thailand and Risk Assessment 3.1 Opportunities and Policy Direction Despite regulatory tightening, the government continues to view cannabis as a sector with high potential for: Medical tourism and integrative health services. Pharmaceutical production of cannabis-derived medicines with EU-GMP certification Agriculture, with cannabis and hemp positioned as high-value crops under Thai GACP standard. Industrial hemp exports, including textiles, food supplements, and construction materials. While rumors persist that the government may recriminalize cannabis, such a move would face strong resistance—including potential class actions from over one million licensed cannabis operators. More realistically, cannabis will remain regulated for medical, industrial, and research purposes, rather than being reclassified as a narcotic. 3.2 Risks in Cannabis Business Regulatory Uncertainty Laws remain in flux. Political changes or international obligations may prompt abrupt policy reversals. Example: The 2022–2023 decriminalization wave was quickly followed by 2024–2025 restrictive reforms. Criminal Liability Unauthorized possession, sale, or use outside of medical purposes may trigger penalties under the Narcotics Act B.E. 2522 (1979) or ministerial cannabis regulations. High risk: Dispensing cannabis flowers or >0.2% THC distillates without a prescription may result in imprisonment, fines, and license revocation. Public Health and Social Concerns Businesses risk reputational damage if they are linked to recreational misuse, underage sales, or public nuisance. Such events may also lead to license suspension by the FDA. Foreign Investor Restrictions The Foreign Business Act limits foreign participation in agriculture and cannabis-related services, unless exemptions are granted. Banking and Financing Risks Cannabis remains a “no-bank” sector in Thailand. Commercial banks typically refuse financing, credit facilities, or lending to cannabis operators due to compliance risks and reputational concerns. Cross-Border Legal Conflicts Exporting cannabis products without authorization can violate ASEAN neighbors’ narcotics laws, leading to severe penalties. Exporters must hold FDA export licenses, while importers must obtain permits from the destination country. Compliance and Licensing Costs Meeting Thai GACP and GMP standards requires significant investment. Smaller operators may be priced out, resulting in consolidation favoring larger, well-capitalized firms. 3.3 Risk Mitigation Strategies Robust Legal Due Diligence: Review licensing requirements, corporate structure, and contracts with a qualified legal counsel. Strict Prescription Protocols: Employ licensed doctors and establish patient consultation systems for the prescription of cannabis flowers and high-THC distillates. Regulatory Monitoring: Retain compliance teams or external counsel to monitor ministerial notifications and regulatory changes. Corporate Structuring: Form vetted joint ventures with reliable Thai partners, and conduct strict due diligence to avoid fraudulent actors in the market. Product & Marketing Compliance: Adhere to THC content limits, labeling rules, and advertising restrictions, and avoid recreational branding. Risk Management & Insurance: Obtain liability insurance and adopt strong corporate governance policies. Diversification: Focus on industrial hemp, medical cannabis, and pharmaceutical-grade extracts, which carry fewer political and legal risks. Cross-Border Legal Review: Secure legal opinions in both Thailand and the destination countries to ensure compliance with international drug control treaties. Conclusion The cannabis industry in Thailand represents both opportunity and risk. Thailand stands as a pioneer in Southeast Asia, opening pathways for medical, wellness, and industrial cannabis. Yet the regulatory environment remains fluid, and businesses face legal, financial, and reputational challenges Of particular importance is the strict requirement that cannabis flowers and all cannabis distillates with more than 0.2% THC w/w can only be sold with a doctor’s prescription. Violations in this area carry serious criminal and civil liabilities and will remain a central enforcement priority going forward. For investors and operators, success depends on rigorous compliance, sound structuring, and proactive legal strategy. By aligning with Thailand’s evolving regulatory framework, businesses can capture opportunities while minimizing risk. At ILAWASIA CO., LTD., we provide comprehensive legal support for cannabis operators. Our Partner, Mr. Tanadee Pantumkomon, is one of the most experienced counsels in Thailand on cannabis cultivation, extraction, and product manufacturing. Our services cover FDA licensing and permits, corporate structuring, tax planning, dispute resolution, and cross-border advisory—ensuring that our clients’ investments are secure and compliant. AUTHOR Tanadee Pantumkomon, Partner. He can be reach out at [email protected]

On 26 September 2025, a Notification concerning consumer protection in “wellness services” was promulgated in the Royal Gazette. This legal instrument marks a milestone: it imposes clearer obligations and restrictions on wellness-service providers, and strengthens consumers’ rights in an industry long characterized by ambiguity. Scope and Purpose Defining “Wellness Services” Under the Notification, “wellness services” encompasses a wide array of practices aimed at promoting physical, mental, or emotional well-being. These include spa treatments, massages, aromatherapy, beauty and skincare services, as well as holistic or alternative therapies such as energy healing and detox programs. The scope also covers wellness coaching, nutrition counseling, lifestyle programs, and other services are marketed to improve health, appearance, stress levels, or overall vitality. However, services already regulated under other statutes—such as medical treatments under the Medical Act or pharmaceutical services—remain outside the scope of this regulation. Objectives and Rationale The Notification seeks to strengthen consumer protections in a sector where outcomes are often subjective, and marketing can blur the line between facts and promises. It aims to promote transparency and fair dealings by requiring providers to make clear disclosures, avoid misleading claims, and use fair contract terms. In addition, it facilitates regulatory oversight and consumer recourse by mandating record-keeping, establishing complaint channels, and imposing penalties for noncompliance. By doing so, the law raises industry standards, deters abusive practices, and restores consumer trust in wellness providers. Key Provisions: What Providers Must Do—and Must Not Do Prohibited Acts The Notification delineates several categories of prohibited behavior. Providers are barred from misrepresentation or exaggeration, including advertising claims that promise unrealistic benefits without evidence, misuse of scientific or medical terminology, and misleading testimonials or endorsements. They may not omit or conceal essential information such as hidden charges, risks, or contractual limitations. Unfair contract practices are also prohibited, including forcing consumers into long-term obligations without consent, bundling services without alternatives, and penalizing cancellations unreasonably. High-pressure sales tactics, such as coercive upselling or rushed deals, are disallowed. Advertising violations include making unsubstantiated competitor comparisons, offering deceptive “free trials,” or using medical claims without evidence. Finally, recordkeeping failures—such as neglecting to retain or prematurely discarding contracts, receipts, or consumer records—are prohibited. Required Disclosures, Rights, and Duties In addition to prohibitions, providers must fulfill positive duties. They are required to ensure transparent pricing by prominently displaying all costs, fees, and charges. For services above certain thresholds, written contracts must be provided, clearly stating services, schedules, prices, cancellation and refund terms, and liability clauses. Consumers must be given cooling-off and refund rights under fair and reasonable conditions. For services involving risks or side effects, providers must disclose these risks and obtain informed consent. Consumers also have the right to inspect practitioner credentials, facility licenses, and safety or hygiene protocols. Furthermore, providers must retain contracts, logs, and receipts for a legally prescribed period and make them available upon request. Advertising and Marketing Controls Marketing activities are subject to strict regulation. Claims must be substantiated and cannot guarantee results without supporting evidence. Testimonials, endorsements, and before-and-after images must carry appropriate disclaimers such as “results vary.” Any “free” or “bonus” offer must state conditions, eligibility, and limitations. Comparative advertising is permitted only if fair, verifiable, and not disparaging. Finally, providers must avoid misusing scientific or medical language in ways that overstate efficacy. Penalties, Enforcement, and Complaints The Notification empowers regulators with a range of enforcement tools. Operators who infringe the rules may face administrative sanctions or fines. Authorities—including consumer protection agencies and relevant ministries—are authorized to inspect businesses, investigate violations, and order corrective measures, including public disclosure of offenders. Consumers themselves may file complaints to these bodies, which are empowered to mediate, enforce, and even publicly name violators to prevent further harm. Impacts for Consumers and Wellness Providers Benefits for Consumers For consumers, the new law offers greater clarity and stronger safeguards when purchasing wellness services. It ensures recourse in cases of misleading claims, hidden fees, or coercive tactics. Consumers are empowered to demand disclosures, verify credentials, and cancel unfair contracts, while service providers face heightened accountability and improved industry standards. Implications for Wellness Providers For providers, the law requires audits of existing contracts, marketing practices, and operational protocols. Compliance may demand investment in staff training, recordkeeping, and legal review. Smaller businesses may face adjustment challenges, yet compliant providers stand to differentiate themselves, gaining trust and a competitive edge in the marketplace. Conclusion The Notification represents a strong step forward for consumer rights in Thailand’s wellness sector. By setting clear boundaries for marketing, contract fairness, disclosure obligations, and enforcement, it tilts the balance toward transparency and integrity. ILAWASIA stands ready to help bridge the gap between theory and practice. We offer expert guides, complaint support, legal audits, and public outreach to ensure that consumers can exercise their rights with confidence—and that wellness operators adhere to ethical, lawful standards. With ILAWASIA, you’re not just protected by law; you’re empowered to enforce it. Author Tanadee Pantumkomon, Partner. He can be reach out at [email protected]